{"id":"simvastatin","brandName":"Zocor","genericName":"simvastatin","companyId":"merck","companyName":"Merck & Co.","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drugClass":"HMG-CoA Reductase Inhibitor [EPC]"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"14281 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"13884 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"13021 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"12366 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"12117 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"11656 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"9708 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"9696 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"9627 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"9347 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Upper respiratory infection","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Acute coronary syndrome","Acute nephropathy","Acute pancreatitis","Alcoholism","Arterial hemorrhage","Blood coagulation disorder","Breastfeeding (mother)","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Disorder of muscle","Gout","Hemorrhagic cerebral infarction","Hyperglycemia","Hypophosphatemia","Liver function tests abnormal","Low blood pressure","Myocardial infarction","Myopathy related to SLCO1B1 Gene Variant","Peptic ulcer","Pregnancy, function","Rhabdomyolysis","SLCO1B1 Gene Variant for OATP1B1 Transporter Affecting Hepatic Clearance","Surgical procedure","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Myopathy (80 mg daily)","drugRate":"0.9%","severity":"serious"},{"effect":"Rhabdomyolysis (80 mg daily)","drugRate":"0.4%","severity":"serious"},{"effect":"Persistent liver enzyme elevation (>3xULN)","drugRate":"1%","severity":"serious"},{"effect":"Myopathy (40 mg daily)","drugRate":"0.08%","severity":"serious"},{"effect":"Myopathy (20 mg daily)","drugRate":"0.03%","severity":"serious"},{"effect":"Myopathy/Rhabdomyolysis (40 mg daily)","drugRate":"0.1%","severity":"serious"}]},"trials":["NCT00546559","NCT01764451","NCT01634906","NCT00093899","NCT04859452","NCT01979185","NCT00479713","NCT00935259","NCT02817243","NCT05580250","NCT00552097","NCT02187536","NCT00303277","NCT01167894","NCT02129231","NCT00452244","NCT05542095","NCT05658692","NCT03929744","NCT00905905","NCT00486044","NCT01047423","NCT00532311","NCT01138072","NCT02533141","NCT01326676","NCT00125060","NCT00267267","NCT02743364","NCT03419429","NCT02017639","NCT00307307","NCT00254475","NCT06632834","NCT02060032","NCT06478940","NCT02534376","NCT01420328","NCT00650663","NCT00321802","NCT00854503","NCT00546182","NCT04178980","NCT01972178","NCT02120872","NCT00664846","NCT06856772","NCT01294683","NCT00905541","NCT01057758"],"indications":{"approved":[{"name":"Arteriosclerotic vascular disease","diseaseId":"arteriosclerotic-vascular-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cerebrovascular accident","diseaseId":"cerebrovascular-accident","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Familial hypercholesterolemia - heterozygous","diseaseId":"familial-hypercholesterolemia---heterozygous","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Familial hypercholesterolemia - homozygous","diseaseId":"familial-hypercholesterolemia---homozygous","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Familial type 3 hyperlipoproteinemia","diseaseId":"familial-type-3-hyperlipoproteinemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypercholesterolemia","diseaseId":"hypercholesterolemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypertriglyceridemia","diseaseId":"hypertriglyceridemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hypoalphalipoproteinemia","diseaseId":"hypoalphalipoproteinemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mixed hyperlipidemia","diseaseId":"mixed-hyperlipidemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Myocardial Infarction Prevention","diseaseId":"myocardial-infarction-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Transient Ischemic Attacks","diseaseId":"prevention-of-transient-ischemic-attacks","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Slow Progression of Coronary Artery Disease","diseaseId":"slow-progression-of-coronary-artery-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Formulation","number":"9597289","applicant":"SALERNO PHARMACEUTICALS","territory":"US","tradeName":"FLOLIPID","expiryDate":"2030-02-23"},{"type":"Formulation","number":"10300041","applicant":"SALERNO PHARMACEUTICALS","territory":"US","tradeName":"FLOLIPID","expiryDate":"2027-04-26"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT00546559","phase":"N/A","title":"","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","isPivotal":false,"enrollment":0,"indication":"Hypercholesterolemia","completionDate":"2008-03"},{"nctId":"NCT01764451","phase":"EARLY/Phase 1","title":"Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins","status":"TERMINATED","sponsor":"University of New Mexico","isPivotal":false,"enrollment":12,"indication":"Cavernous Angioma, Familial, Cerebral Cavernous Malformations","completionDate":"2016-01"},{"nctId":"NCT01634906","phase":"NA","title":"Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy","status":"COMPLETED","sponsor":"Sint Franciscus Gasthuis","isPivotal":false,"enrollment":55,"indication":"Hyperlipidemia, Atherosclerosis","completionDate":"2013-03"},{"nctId":"NCT00093899","phase":"Phase 3","title":"A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":611,"indication":"Hyperlipidemia, Hypercholesterolemia","completionDate":"2005-09"},{"nctId":"NCT04859452","phase":"Phase 1","title":"A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-Drug Pharmacokinetic Interaction Between DBPR108 at Steady-state and Metformin Hydrochloride/Glibenclamide/Valsartan","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","isPivotal":false,"enrollment":56,"indication":"Healthy Subjects","completionDate":"2021-07-09"},{"nctId":"NCT01979185","phase":"Phase 1","title":"A Phase 1, Randomized, Open-label, Cross-over Study to Evaluate the Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Simvastatin in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shire","isPivotal":false,"enrollment":30,"indication":"Healthy","completionDate":"2013-12-13"},{"nctId":"NCT00479713","phase":"Phase 3","title":"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":618,"indication":"Hypercholesterolemia","completionDate":"2008-03-01"},{"nctId":"NCT00935259","phase":"Phase 1","title":"A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":31,"indication":"Hypercholesterolemia, Dyslipidemia","completionDate":"2009-10"},{"nctId":"NCT02817243","phase":"Phase 1","title":"The Drug Interaction Study of SP2086 and Simvastatin in Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","isPivotal":false,"enrollment":24,"indication":"Type 2 Diabetes","completionDate":""},{"nctId":"NCT05580250","phase":"Phase 1","title":"A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of LY3526318, and to Investigate the Effect of LY3526318 on Metformin and Simva","status":"WITHDRAWN","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":0,"indication":"Healthy","completionDate":"2022-12-08"},{"nctId":"NCT00552097","phase":"Phase 3","title":"Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial)","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":720,"indication":"Atherosclerosis, Hypercholesterolemia","completionDate":"2006-04-25"},{"nctId":"NCT02187536","phase":"Phase 1","title":"Pharmacokinetics of Single Oral Doses of 40 mg Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan 80 mg Daily, Given Orally Over 6 Days. A Rando","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":""},{"nctId":"NCT00303277","phase":"Phase 4","title":"Do HMG CoA Reductase Inhibitors Affect Abeta Levels?","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","isPivotal":false,"enrollment":35,"indication":"Alzheimer's Disease, Aging","completionDate":"2005-04"},{"nctId":"NCT01167894","phase":"Phase 1","title":"A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Simvastatin 80 mg Tablets of Dr. Reddy's to be Compared With Zocor® 80 mg Tablets of Merck & Co. I","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":72,"indication":"Healthy","completionDate":"2005-04"},{"nctId":"NCT02129231","phase":"Phase 2","title":"Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical Trial","status":"COMPLETED","sponsor":"University of Guadalajara","isPivotal":false,"enrollment":74,"indication":"Oxidative Stress, Diabetic Polyneuropathy","completionDate":"2014-04"},{"nctId":"NCT00452244","phase":"Phase 2","title":"Randomized Phase II Trail Comparing Gefitinib Plus Simvastatin and Gefitinib Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"National Cancer Center, Korea","isPivotal":false,"enrollment":110,"indication":"Lung Cancer","completionDate":"2011-03"},{"nctId":"NCT05542095","phase":"Phase 1","title":"Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":0,"indication":"Olfactory Disorder, COVID-19","completionDate":"2023-05-01"},{"nctId":"NCT05658692","phase":"Phase 4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":1000,"indication":"Acute Respiratory Distress Syndrome","completionDate":"2023-12"},{"nctId":"NCT03929744","phase":"Phase 1","title":"A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":133,"indication":"Healthy","completionDate":"2020-11-02"},{"nctId":"NCT00905905","phase":"Phase 4","title":"Additive Effect of Ezetimibe Upon Simvastatin Treatment on Systemic Inflammatory Activity and Endothelial Function During Myocardial Infarction","status":"COMPLETED","sponsor":"Brasilia Heart Study Group","isPivotal":false,"enrollment":40,"indication":"Myocardial Infarction","completionDate":"2010-01"},{"nctId":"NCT00486044","phase":"Phase 2","title":"Effect of Statins on Pathobiology of Alzheimer's Disease","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","isPivotal":false,"enrollment":103,"indication":"Alzheimer Disease","completionDate":"2009-06"},{"nctId":"NCT01047423","phase":"Phase 4","title":"Targeting Microvascular Dysfunction in Young Hypertensive Patients","status":"WITHDRAWN","sponsor":"Queen's University, Belfast","isPivotal":false,"enrollment":0,"indication":"Hypertension","completionDate":"2011-08"},{"nctId":"NCT00532311","phase":"Phase 3","title":"A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg or Placebo When Co-administered With Statins in Subjects With Hypercholesterolemia, With an Optional O","status":"TERMINATED","sponsor":"Takeda","isPivotal":true,"enrollment":411,"indication":"Hypercholesterolemia","completionDate":"2008-04"},{"nctId":"NCT01138072","phase":"Phase 1","title":"A Phase I, Single-center, Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":14,"indication":"Infection, Human Immunodeficiency Virus","completionDate":"2010-08"},{"nctId":"NCT02533141","phase":"Phase 4","title":"Effect of Simvastatin Withdrawal on Ocular Endothelial Function","status":"WITHDRAWN","sponsor":"Medical University of Vienna","isPivotal":false,"enrollment":0,"indication":"Healthy","completionDate":"2020-12"},{"nctId":"NCT01326676","phase":"Phase 3","title":"PESCA - A Randomised Controlled Trial of a Cardiovascular Polypill Treatment Strategy Compared With Usual Care on Carotid Intima-media Thickness in Individuals at High Risk of Cardiovascular Disease","status":"WITHDRAWN","sponsor":"Imperial College London","isPivotal":true,"enrollment":0,"indication":"Cardiovascular Disease","completionDate":"2012-09"},{"nctId":"NCT00125060","phase":"NA","title":"Transesophageal MRI in Conjunction With Lipid Lowering Measures","status":"COMPLETED","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":72,"indication":"Heart Diseases","completionDate":"2004-04"},{"nctId":"NCT00267267","phase":"Phase 3","title":"Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Comb","status":"TERMINATED","sponsor":"Pfizer","isPivotal":true,"enrollment":1784,"indication":"Hyperlipidemia, Dyslipidemia","completionDate":"2007-01"},{"nctId":"NCT02743364","phase":"Phase 2","title":"Statin Therapy to Reduce the Risk of Recurrent Pancreatitis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":8,"indication":"Acute Pancreatitis","completionDate":"2022-05-11"},{"nctId":"NCT03419429","phase":"Phase 4","title":"The Use of Simvastatin Gel With Perforated Resorbable Membranes in the Treatment of Intrabony Defects in Chronic Periodontitis Patients (Clinical and Biochemical Study)","status":"COMPLETED","sponsor":"Ain Shams University","isPivotal":false,"enrollment":40,"indication":"Chronic Periodontitis","completionDate":"2017-06"},{"nctId":"NCT02017639","phase":"Phase 1","title":"A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Do","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":19,"indication":"Rheumatoid Arthritis","completionDate":"2016-03"},{"nctId":"NCT00307307","phase":"Phase 4","title":"Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology","status":"COMPLETED","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":69,"indication":"Established Carotid Atherosclerosis","completionDate":"2005-09"},{"nctId":"NCT00254475","phase":"Phase 3","title":"A Study to Evaluate the Efficacy of the Valsartan/Simvastatin Combinations 160/20mg up Titrated to 320/20mg Versus 160/40mg up Titrated to 320/40mg in Patients With Both Essential Hypertension and Hyp","status":"COMPLETED","sponsor":"Novartis","isPivotal":true,"enrollment":871,"indication":"Essential Hypertension, Hypercholesterolemia","completionDate":"2006-09"},{"nctId":"NCT06632834","phase":"Phase 2","title":"Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study, and Phenotype-genotype Correlation","status":"RECRUITING","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":230,"indication":"Dilated Cardiomyopathy","completionDate":"2025-01-19"},{"nctId":"NCT02060032","phase":"Phase 2","title":"COMPARATIVE EVALUATION OF CLINICAL EFFICACY OF SUBGINGIVALLY DELIVERED 1.2% ATORVASTATIN AND 1.2% SIMVASTATIN IN TREATMENT OF CHRONIC PERIODONTITIS: A RANDOMIZED CONTROLLED TRIAL","status":"COMPLETED","sponsor":"Government Dental College and Research Institute, Bangalore","isPivotal":true,"enrollment":96,"indication":"Chronic Periodontitis","completionDate":"2013-11"},{"nctId":"NCT06478940","phase":"Phase 1","title":"Clinical and Radiographic Evaluation of 3Mixtatin Versus MTA Used as Pulpotomy Agents in Vital Primary Molars: A Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","isPivotal":false,"enrollment":50,"indication":"Pulp Disease, Dental, Deciduous Teeth","completionDate":"2025-09-01"},{"nctId":"NCT02534376","phase":"EARLY/Phase 1","title":"Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","isPivotal":false,"enrollment":63,"indication":"Prostate Cancer","completionDate":"2019-02-28"},{"nctId":"NCT01420328","phase":"NA","title":"To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects","status":"COMPLETED","sponsor":"University at Buffalo","isPivotal":false,"enrollment":20,"indication":"Inflammation","completionDate":"2016-07-01"},{"nctId":"NCT00650663","phase":"Phase 4","title":"A Multicenter, Double-Blind, Randomized Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of Ezetimibe Coadministered With Simvastatin Versus Simvastatin Monotherapy in African-A","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":247,"indication":"Hypercholesterolemia, Atherosclerosis","completionDate":"2004-09-01"},{"nctId":"NCT00321802","phase":"Phase 2","title":"Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins","status":"COMPLETED","sponsor":"University of Calgary","isPivotal":false,"enrollment":40,"indication":"Atrial Fibrillation","completionDate":"2012-12"},{"nctId":"NCT00854503","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","isPivotal":true,"enrollment":30,"indication":"Type 2 Diabetes, Diabetic Dyslipidemia","completionDate":"2010-12"},{"nctId":"NCT00546182","phase":"N/A","title":"Phase 4 Study of Simvastatin That Affects Insulin Sensitivity","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","isPivotal":false,"enrollment":0,"indication":"Hypercholesterolemia","completionDate":""},{"nctId":"NCT04178980","phase":"Phase 1","title":"Double-blinded, Randomized Controlled Trial of Simvastatin Use As Adjuvant Therapy in Relapsing-Remitting Multiple Sclerosis","status":"UNKNOWN","sponsor":"Assiut University","isPivotal":false,"enrollment":60,"indication":"Simvastatin Multiple Sclerosis","completionDate":"2022-03-01"},{"nctId":"NCT01972178","phase":"Phase 2","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Su","status":"TERMINATED","sponsor":"Pronova BioPharma","isPivotal":false,"enrollment":113,"indication":"Dyslipidemia","completionDate":"2014-08"},{"nctId":"NCT02120872","phase":"Phase 2","title":"Platelet - Rich Fibrin Combined With 1.2mg Simvastatin for the Treatment of 3 - Wall Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial","status":"COMPLETED","sponsor":"Government Dental College and Research Institute, Bangalore","isPivotal":false,"enrollment":90,"indication":"Three Wall Intrabony Defects in Chronic Periodontitis","completionDate":"2014-01"},{"nctId":"NCT00664846","phase":"NA","title":"Standard Medical Management in Secondary Prevention of Ischemic Stroke in China.","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","isPivotal":false,"enrollment":4000,"indication":"Stroke","completionDate":"2011-04"},{"nctId":"NCT06856772","phase":"Phase 4","title":"Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","isPivotal":false,"enrollment":42000,"indication":"Cardiovascular Diseases (CVD), Drug Effect","completionDate":"2028-03-28"},{"nctId":"NCT01294683","phase":"Phase 3","title":"A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients With Prim","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":977,"indication":"Primary Hypercholesterolemia, Dyslipidemia","completionDate":"2012-01-17"},{"nctId":"NCT00905541","phase":"NA","title":"Influence of Simvastatin on apoB-100 Secretion in Non-Obese Subjects With Moderate Hypercholesterolemia: A Stable Isotope Study","status":"COMPLETED","sponsor":"University Hospital, Bonn","isPivotal":false,"enrollment":8,"indication":"Hypercholesterolemia","completionDate":"2000-03"},{"nctId":"NCT01057758","phase":"Phase 3","title":"Effect of the Association of a Statin to Antibiotics on the Prognosis of Patients Presenting With a Suspicion of Ventilator-associated Pneumonia","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","isPivotal":true,"enrollment":300,"indication":"Pneumonia","completionDate":"2013-06"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0359/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$13","description":"SIMVASTATIN 10 MG TABLET","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-11-20T00:00:00.000Z","mah":"LUPIN","brand_name_local":null,"application_number":"ANDA078103"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-02-02T00:00:00.000Z","mah":"ORGANON","brand_name_local":null,"application_number":"NDA021687"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-09-26T00:00:00.000Z","mah":"AMNEAL PHARMS CO","brand_name_local":null,"application_number":"ANDA208831"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-13T00:00:00.000Z","mah":"ACCORD HLTHCARE","brand_name_local":null,"application_number":"ANDA078155"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-12-16T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA209222"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"10300041","territory":"US","patent_type":"Formulation","expiry_date":"2027-04-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9597289","territory":"US","patent_type":"Formulation","expiry_date":"2030-02-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":23,"withResults":7},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=simvastatin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:19:04.493650+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:19:04.493589+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:19:10.519435+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:19:03.504486+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=simvastatin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:19:10.829109+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:55.937962+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:55.937991+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:55.937997+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:19:12.371334+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201391/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:11.527389+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA078103","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:55.937999+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:19:15.915120+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL1201391"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}